BEIGENE-BGB-11417-301
Phase III
OPEN TO ACCRUAL
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia
CARNABIOSCIENCES-C1763102
Phase I
OPEN TO ACCRUAL
A Phase 1b Study of Oral AS-1763 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non Hodgkin Lymphoma
IIT-SHAH-IL7-IL15-CD20-19
Phase I/II
OPEN TO ACCRUAL
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies
MERCK-MK2140-006-CLL-NHL
Phase II
OPEN TO ACCRUAL
A Multicenter, Open-Label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-Cell Malignancies
NOVARTIS-YTB323A12101
Phase I
OPEN TO ACCRUAL
Phase 1, Open Label, Multicenter, Dose Escalation Study of YTB323 in Adult Patients with CLL/SLL and DLBCL
SCHRODINGER-SGR-1505-101
Phase I
OPEN TO ACCRUAL
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Patients with Mature B-Cell Malignancies